Medgenics, Inc. Announces Registration of Shares to Be Issued upon Exercises of Warrants Listed on NYSE MKT

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and MDGN.WS and AIM: MEDG and MEDU), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced the availability of a current prospectus following the effectiveness of its registration in the United States of common stock issuable upon the exercise of outstanding warrants to purchase 2,829,000 shares of common stock.